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Abstract
Nature has provided us with a wide spectrum of disease healing phytochemicals like Artonin
E, obtained from the root bark of Artocarpus elasticus. This molecule had been predicted to
be drug-like, possessing unique medicinal properties. Despite strides made in chemotherapy,
prognosis of the heterogenous aggressive triple negative breast cancer is still poor. This
study was conducted to investigate the mechanism of inhibition of Artonin E, a prenylated fla-
vonoid on MDA-MB 231 triple negative breast cancer cell, with a view of mitigating the hall-
marks displayed by these tumors. The anti-proliferative effect, mode of cell death and the
mechanism of apoptosis induction were investigated. Artonin E, was seen to effectively relin-
quish MDA-MB 231 breast cancer cells of their apoptosis evading capacity, causing a half-
maximal growth inhibition at low concentrations (14.3, 13.9 and 9.8 μM) after the tested time
points (24, 48 and 72 hours), respectively. The mode of cell death was observed to be apo-
ptosis with defined characteristics. Artonin E was seen to induce the activation of both extrin-
sic and intrinsic caspases initiators of apoptosis. It also enhanced the release of total reactive
oxygen species which polarized the mitochondrial membrane, compounding the release of
cytochrome c. Gene expression studies revealed the upregulation of TNF-related apoptosis
inducing ligand and proapoptotic genes with down regulation of anti-apoptotic genes and pro-
teins. A G2/M cell cycle arrest was also observed and was attributed to the observed upregu-
lation of p21 independent of the p53 status. Interestingly, livin, a new member of the inhibitors
of apoptosis was confirmed to be significantly repressed. In all, Artonin E showed the poten-
tial as a promising candidate to combat the aggressive triple negative breast cancer.
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Introduction
Breast cancer is a complex and heterogeneous disease, constituting an enormous burden to the
world at large with increasing mortality rates. It is the most frequently diagnosed cancer and
unfortunately the leading cause of cancer death among women [1] with an estimated 1.67 mil-
lion new cases diagnosed in the year 2012 [2]. Epidemiologic studies have outlined both
genetic and non-genetic factors that contribute to the development and progression of breast
cancer at all stages. Only between 5 to 10% of breast cancers are hereditary. Between 90 to 95%
of breast cancer cases are attributed to environmental factors [3], [4] including age (at menar-
che, menopause and first pregnancy) [5], diet, smoking and alcohol consumption [6], lack of
physical activity [7] and the use of oral contraceptives [8].
Notable among breast cancer cases, are the triple negative breast cancers. These cancers are
highly aggressive by nature and are characterized by the absence of hormone receptors [9].
Like other cancers, it shares the unique hallmark of apoptosis evasion while on the path to
immortality, a contributor to drug responsiveness [10]. There are two major pathways of apo-
ptosis viz: the extrinsic and mitochondrial (intrinsic) pathways [11]. Both pathways are con-
trolled by a number of gene families which finally lead to the phagocytosis of cells by adjacent
cells [12], [13]. In spite of the unique attribute of conventional chemotherapies in inducing
apoptosis, many of them are constantly facing resistance coupled with their alarming side
effects. Even with the strides to lessen the burden of breast cancer, the prognosis of triple breast
cancer is still poor [14] [15]. This flurry encouraged the search into natural sources for rela-
tively safe alternatives to ameliorate the clinical consequences of the hormone negative breast
cancer.
Currently, natural products and their derivatives represent more than 50% of the widely
used anticancer drugs[16][17]. Artonin E, 5-hydroxy-8,8-dimethyl-3-(3-methylbut-2-enyl)-2-
(2,4,5-trihydroxyphenyl) pyrano [2,3-h]chromen-4-one, is a prenylated flavonoid isolated
from the stem bark of Artocarpus elasticus [18]. This compound has been shown to possess
several biological activities including arachidonate 5-lipoxigenase inhibition, antibacterial and
anticandicidal [19] antimalarial[20][21], anticancer [22][17] and antiestrogenic [23]. Recently,
we reported the mitochondrial dysregulation of Artonin E in ovarian cancer [18] as well as its
antiestrogenic capacity [23]. However, the antitumor molecular mechanism of Artonin E in
triple negative breast cancer, to the best of our knowledge has not yet been reported. This
study, utilizes in vitro molecular investigations to elucidate the mechanism of Artonin E in the
invasive triple negative breast cancer cell line, MDA-MB 231.
Materials and method
Preparation of test agents
Artonin E was extracted from the root bark of Artocarpus elasticus and characterized as we pre-
viously reported [18]. The standard agents, Tamoxifen and Paclitaxel were purchased from
Sigma Aldrich, St. Louis, MO, USA. These agents were dissolved in DMSO and diluted with
respective medium with highest final DMSO concentration of 0.1% for the in vitro cell culture
studies.
Cell viability study
The colorimetric microculture tetrazolium assay (MTT) was used to study the viability of
MDAMB 231 cells in accordance to Mosmann (1983) [24]. Briefly, exponentially growing cells
were seeded in a 96-well flat bottom tissue culture plate at a density of 0.5 × 104 cells/well. The
cells were thereafter treated after 24 hours incubation with different concentration (1.56 to
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100 μM) of Artonin E. After the treatment incubation period (24±72 hours), 20 μL of 5 mg/mL
of MTT solution was added to each well and the plate was reincubated for 4 hours to facilitate
catalysis by mitochondrial dehydrogenases and then solubilized with 100 μL of DMSO. The
amount of purple formazan formed was measured colorimetrically at 570 nm. The experiment
was done in triplicate. A nonlinear regression analysis was performed and a dose-response
curve was fitted using the GraphPad Prism software. The concentration of each agent that
evoked a 50% growth inhibition and the 95% confidence interval were determined using the
GraphPad Prism software. The dose-response curve was fitted with the percentage viability
calculated from the following formula:
% of cell viability 
AT
AC
 100 1
Where AT is the absorbance reading of treated samples and AC the absorbance of control sam-
ples treated with 0.1% of DMSO equivalent.
Cell morphological study
Acridine orange (AO) and Propidium iodide (PI) double staining assay was used to investigate
the morphological changes in Artonin E-treated breast cancer cell. A total of 3 × 105
MDA-MB-231 breast cancer cells was seeded in a six-well plate and allowed to adhere over-
night before treatment with various concentrations of Artonin E (3, 10 and 30 μM) at various
time periods (24 and 48 hours). After trypsinization, the cells were centrifuged at 2000 rpm
(Hettich Universal 32 R centrifuge, DJB Labcare Ltd, UK) for 5 minutes and the pellet was
washed with ice-cold PBS, re-centrifuged before suspending in 20 μL of PBS. The cells were
thereafter stained on ice with 20 μL dye containing 10 μg/mL of AO with 10 μg/mL of PI. Ali-
quots of 20 μL of the cell suspension were examined under Carl Zeiss Axioskop plus-2 fluores-
cence microscope. At least 200 cells in each of three fields were immediately assessed for
viability, early, late apoptosis and necrosis [12]. The experiment was carried out in triplicate.
Annexin V-FITC assay
The annexin V-FITC assay was performed using the Annexin V Kit (BD Pharmingen, USA) to
investigate apoptosis via detecting externalized phosphatidylserine. Briefly, after trypsiniza-
tion, the treated cells in the 6-well plate was collected, washed with ice-cold PBS, resuspended
in 1X binding buffer before transferring to BD Falcon flow cytometry tubes. Next, 5μL each of
PI solution and annexin V-FITC conjugate were added to the cell gently mixed and incubated
for 20 minutes at room temperature in the dark. The cells were finally subjected to flowcyto-
metric analysis using laser emitting excitation light at 488 nm and a BD flow cytometer
equipped with an Argon laser (Cyan ADP, DAKO, Glostrup, Denmark). The experiment was
carried out in triplicate and the data were analyzed using the Summit V4.3 software.
DNA fragmentation analysis
Qualitative DNA fragmentation (Roche) kit was used in this analysis. Briefly, DNA from
Artonin E treated and untreated MDA-MB 231 cells were extracted in accordance with the
manufacturer's protocol. The quality of the extracted DNA was assessed with a nanodrop spec-
trophotometer (nanodrop lite spectrophotometer, Thermo scientific, USA). The extracted
DNA sample was mixed with 1X loading dye and run on 1% agarose gel at 75 V for 1 hour in
triplicate. The fragmented DNA was visualized under UV transilluminator and photographed
under Gel Doc (Bio-rad, Hercules, CA, US).
Artonin E and MDA-MB 231 triple negative breast cancer cells
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Flowcytometry cell cycle analysis
The cell cycle analysis was investigated using the BD Cyclestest Plus DNA Kit (BD Biosci-
ences, San Jose, CA, US) according to the manufacturer's instruction. Briefly, the cells
was seeded in a T25 tissue culture flask at a density of 1 × 106 cells/flask and allowed to
stand overnight in the incubator for attachment prior to treatment with 3, 10 and 30 μM of
Artonin E. Treated cell were trypsinized, collected and centrifuged at 3000 rpm (Hettich
Universal 32 R centrifuge, DJB Labcare Ltd, UK) for 5 minutes. The supernatant was dis-
carded and the cells were washed twice with 1 mL of buffer consisting of sodium citrate,
sucrose and DMSO. For the staining procedure, the cell suspension was transferred into a
flow cytometry tube and 250 μL of solution A (trypsin buffer) was added to each tube,
mixed gently and allowed to react for 10 minutes at room temperature. Solution B, consist-
ing of trypsin inhibitor and RNase buffer was thereafter added to the same tubes and
allowed to incubate for another 10 minutes at room temperature. Two hundred microliters
of ice-cold solution C comprising of propidium iodide (PI) was then added to the same
tubes mixed by gentle tapping and allowed to incubate in the dark on ice for another 10
minutes. The stained MDA-MB 231 samples were directly analyzed using BD FACS Calibur
flow cytometer (Becton Dickson, Biosciences, San Jose, CA, US). The experiment was car-
ried out in triplicate.
Caspase 8 and 9 fluorimetric assay
The activities of caspases 8 and 9 in the breast cancer cells were determined using a commer-
cial fluorimetric assay kit (R&D System) based on spectrophotometric detection. Briefly, the
MDA-MB-231 cells were seeded in T25 flask at a density of 1 × 106 cells/flask. After attach-
ment, the cells were treated with 3, 10 and 30 μM of Artonin E for 24 hours. The cells were
trypsinized and centrifuged at 2,500 rpm Hettich Universal 32 R centrifuge, DJB Labcare
Ltd, UK) in a conical tube for 10 minutes. The cell pellet was lysed by the addition of 50 μL of
cold lysis buffer containing 10 μg/mL of Aproptinin, μg/mL of Leupeptin and 10 μg/mL of
Pepstatin. The cell lysates were incubated on ice for 10 minutes and then centrifuged at
13,000 rpm (Eppendorf 5424 microcentrifuge, USA) for 1 minute before protein quantifica-
tion using Pierce BCA Protein Assay Kit. Two hundred microgram of protein in 50 μl solu-
tions from each of the samples was added to a 96 well flat black bottom microplate, followed
by the addition of 50 μL 2X reaction buffer 8 or 9, as appropriate, containing 10 μL dithio-
threitol (DTT)/mL reaction buffer. For each reaction well, 5 μL of either caspase 8 or 9
fluorogenic substrate (LEHD-AFC) was added and the plate was incubated at 37ÊC for two
hours. Control wells were without treatment. Three independent experiments were carried
out. Finally, the plate was read with a fluorescence microplate reader at an excitation of 400
nm and emission of 505 nm.
Measurement of reactive oxygen species (ROS) production
To evaluate the production of total ROS, the total ROS assay kit (ebioscience Inc, Affymetrix)
was employed in accordance with the manufacturer's instructions. Briefly, the breast cancer
cells at a density of 1 × 106 cells/T25 flask were treated with 3, 10 and 30 μM of Artonin E for
24 hours, trypsinized and centrifuged at 2000 rpm (Hettich Universal 32 R centrifuge, DJB
Labcare Ltd, UK) for 5 minutes. The cells were resuspended in PBS and incubated in 100 μL of
ROS assay stain in buffer solution in a 37ÊC incubator for 60 minutes. The cell sample was
then analyzed by flow cytometry.
Artonin E and MDA-MB 231 triple negative breast cancer cells
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Multiplex mRNA expression analysis
RNA isolation. A 3 mL suspension containing 3 × 105 MDA-MB 231 breast cancer cells
were transferred into each well of a 6-well plate and treated for 24 hours with 3, 10 and 30 μM
of Artonin E. Total RNA was extracted from the cells using the Total RNA extraction kit (GF-
1 TRE kit, Vivantis technologies) according to the manufacturer's protocol. The purity and
concentration of the isolated RNA were ascertained using a spectrophotometer (Beckman
Coulter), USA.
Reverse transcription and polymerase chain reaction. The reverse transcriptase quanti-
tative PCR (RT-qPCR) was carried out according to the GenomeLab GeXP Start Kit (Beckman
Coulter, USA) protocol, in an XP Thermal Cycler (Bioer Technology, Germany). The reaction
was set to run for 1 minute at 48ÊC, 60 minutes at 42ÊC and 5 minutes at 95ÊC. The cDNA pro-
duced was amplified in a PCR reaction consisting of 2 mL of 5X PCR buffer, 2 μL magnesium
chloride, 1 μL of forward primers mixture (Table 1), 0.35 μL of Taq polymerase, and 4.65 μL
cDNA. This reaction was run on the XP Thermal Cycler with an initial denaturation at 95ÊC
for 10 minutes, followed by two-step cycles at 94ÊC for 30 seconds and at 55ÊC for 30 seconds,
and ending with a single-extension cycle at 68ÊC for 1 minute. The primers for the genes of
interest and housekeeping gene (Table 1) were designed on NCBI website and purchased from
Biosune (Shanghai, China), while the internal control (Kanr) was supplied by Beckman Coul-
ter (USA).
Separation of PCR products by GeXP genetic analysis system. The PCR products were
separated by capillary gel electrophoresis and analyzed using the GeXP machine (Beckman
Coulter, Inc.) and the results were analyzed with the fragment analysis module of the GeXP
system software and normalized with β-actin on the eXpress Profiler software.
Proteome profiling of human apoptotic—related proteins
To investigate the effects of Artonin E on the expression pattern of human apoptosis-related
proteins, the proteome profiling was investigated using the human apoptosis array kit (R&D
Systems, USA), according to the manufacturers' protocol. The proteins from the treated and
untreated breast cancer cells were harvested and quantified using the BCA pierce protein
quantification kit. The membranes were first blocked in the Array Buffer 1 in a 4-well multi-
dish with 1-hour incubation on a rocking platform shaker. At the same time, 200 μg of protein
from each sample was incubated in array buffer 1 at room temperature for 60 minutes. After
blocking the membranes, the array buffer 1 was aspirated; the prepared protein samples were
added and incubated with the membrane at 4ÊC overnight on a rocking platform shaker. The
following day, each array was carefully removed and washed thrice with 1X washing buffer on
a rocking platform. For each of the arrays, 15 μL of the reconstituted biotinylated detection
antibody cocktail diluted to 1.5 mL with 1X array buffer 2/3 was used to incubate each array
Table 1. The accession number and sequence of the primers used in the gene expression studies.
Genes Accession
Number
Forward primers Reverse Primers
Caspase 7 NM_033338 5' AGGTGACACTATAGAATAGCTTCTTATGTTACCCAGAT 3' 5' GTACGACTCACTATAGGGAGGTGACATTTTTCTTCTTCT3'
Caspase 8 NM_001228 5' AGGTGACACTATAGAATAGTGCGTCCACTTTCTG3' 5' GTACGACTCACTATAGGGAGGCCAGATCTTCACTGT 3'
Caspase 9 NM_032996 5' AGGTGACACTATAGAATAGCTGGTGGAAGAGCTG3' 5' GTACGACTCACTATAGGGACTCTAAGCAGGAGATGAACA3'
Cyclin E NM_001238 5' AGGTGACACTATAGAATACAGGATCCAGATGAAGAA 3' 5' GTACGACTCACTATAGGGACCTTAAGTATGTCTTTTCCTT3'
P21 NM_000389 5' AGGTGACACTATAGAATAAGCTGAGGTGTGAGCAG 3' 5' GTACGACTCACTATAGGGACCCAGGCGAAGTCAC 3'
ACTB NM_001101 5' AGGTGACACTATAGAATAGATCATTGCTCCTCCTGAGC 3' 5' GTACGACTCACTATAGGGAAAAGCCATGCCAATCTCATC3'
https://doi.org/10.1371/journal.pone.0182357.t001
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for 1 hour on a rocking platform. Thereafter, the arrays were again washed thrice with 1X
array buffer. A 1:2000 dilution of the streptavidin-HRP in 1X Array Buffer 2/3 was used to
incubate each of the membrane for 30 minutes on a rocking platform shaker. Following incu-
bation, the arrays were washed thrice with 1X wash buffer. Finally the membranes were care-
fully removed, placed in a sheet protector and layered with chemiluminiscence reagent before
viewing them with the ChemiDoc XRS (Bio-rad, USA). The experiment was done in three
replicate.
Western blot
Isolation of total protein. Total protein was extracted from 1 × 106 cells/T25 of MDA-
MB-231 cells after 24 hours of treatment with 3, 10 and 30 μM of Artonin E. Briefly, treated
and untreated samples were lysed with 100 μL RIPA lysis buffer containing 1 μL of E-64 prote-
ase inhibitor cocktail. The pellet was resuspended thoroughly and incubated at 4ÊC for 30 min-
utes with agitation before centrifuging it at 10,000 rpm (Eppendorf 5424 Microcentrifuge,
USA) for 10 minutes. The supernatant was thereafter transferred into fresh Eppendorf tubes
and the concentration of the extracted proteins was quantified using Pierce BCA protein assay
kit by microplate assay (universal microplate reader, Biotech, Inc, USA). This was done in
three replicates.
Protein separation. The protein sample (20μg) was separated by electrophoresis on an
SDS-polyacrylamide gel [25] which was subjected to an electrical current of 100 V for 30 min-
utes, followed by 150 V for 1 h to separate the proteins.
Semi-dry transfer and immunodetection. The separated proteins were transfered onto a
polyvinylidene difluoride membrane (Bio-rad, Hercules, CA, US) using a semi-dry transblot
turbo (Bio-rad, Hercules, CA, US). The electrotransfer was performed for 15 minutes at 15 V
per blot of 1.0 mm thick gels. Upon completion of the transfer, the membrane was washed
with water for 5 minutes and blocked with 5% nonfat milk in 1X PBST for 1 hour with agita-
tion on a Belly Dancer1 (Stovall, Life Science Incorporated, North Carolina, USA). The mem-
brane was thereafter washed thrice in TBST with agitation and blocked overnight at 4ÊC with
the respective specific primary antibody to subunit Bcl-2, Bax, livin, p53 and p21 at 1:1000
dilution in TBST with constant agitation. The target proteins were finally detected after label-
ling with goatÐanti-mouse IgG conjugated to horseradish peroxidase. The immunoreacted
protein bands were developed and detected using a chemiluminescence blotting substrate kit
(ECL Western blot substrate, Abcam, England). A chemiluminescence image analyzer system
(Chemi-Smart, Vilber Lourmat, Germany) was thereafter used to view the membranes and the
intensities of band were quantified with the Image Lab software (BioTechniques,USA).
Statistical analysis
The results are expressed as mean ± SD for at least three replicate analyses for each sample in
each assay. Data analysis was performed using GraphPad Prism 5.0 (GraphPad Software Inc.,
La Jolla, CA, USA). One way analyses of variance was performed, followed by Turkey's post
hoc tests to compare replicate means of treatment and control groups. The significance was set
at p<0.05.
Results
Artonin E inhibits the proliferation of MDA-MB 231 cancer cells
The growth inhibitory effect of Artonin E was investigated on MDA-MB 231 breast cancer
cells as well as on the normal breast epithelial cells. From the results, Artonin E, showed a
Artonin E and MDA-MB 231 triple negative breast cancer cells
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significant (p<0.05) time dependent growth inhibitory effect with half maximal inhibitory
concentrations (IC50) of 14.13, 13.93 and 9.77 μM at 24, 48 and 72 hours, respectively (Fig 1).
The cytotoxic effect of standard agents, Paclitaxel and Tamoxifen were also determined as
well as their 95% confidence interval (Table 2). Artonin E was also observed to be more cyto-
toxic and selective towards the cancer cells (selectivity index of 4.68) than Tamoxifen with a
selectivity index of 1.08.
Artonin E induced apoptosis in MDA-MB 231 breast cancer cells
Artonin E induced chromatin condensation and nuclear fragmentation in MDA-MB
231 cancer cells. The acridine orange (AO) and propidium iodide (PI) double staining analy-
sis revealed the morphology of apoptosis in Artonin E-treated MDA-MB 231 breast cancer
Fig 1. The percentage of MDA-MB-231 cell line viability after treatment with Artonin E. The experiment
was done in triplicate at 24, 48, and 72 hours and each point are presented as mean ± SD.
https://doi.org/10.1371/journal.pone.0182357.g001
Table 2. The average half-maximal inhibitory concentrations (IC50) of Artonin E, and standard agents, Tamoxifen and Paclitaxel on MDA-MB 231
and MCF-10A cell lines.
Cell lines Artonin E Paclitaxel Tamoxifen
IC50 (μM) 95% CI IC50 (μM) 95% CI IC50 (μM) 95% CI
MDA-MB 231 9.77±0.50 8.59–11.12 0.05±0.00 0.03–0.11 23.21±0.86 21.49–25.07
MCF-10A 45.80±3.60 42.28–49.60 1.01±0.01 0.73–1.41 25.00±0.30 22.29–28.04
With the exception of those expressed as ranges, all values are presented as means ± standard deviation. IC50 = half maximal growth inhibition;
CI = confidence interval.
https://doi.org/10.1371/journal.pone.0182357.t002
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cells in a concentration- and time-dependent manner in comparison to the untreated cells.
The affected cells exhibited characteristic features of apoptosis like chromatin condensation
and membrane blebbing (Fig 2). The normal nuclear structure of the untreated cells was dis-
played as green fluorescence, whereas bright green fluorescence was shown in early apoptotic
cells, caused by interposition of acridine orange with the fragmented DNA. The binding of
propidium iodine to denatured DNA was identified by reddish-orange color indicating the
late stage of apoptosis. The proportion of viable MDA-MB 231 cells after treatment with Arto-
nin E decreased from 92% in the control to 88% after 24 hours of treatment with 3 μM of Arto-
nin E (Fig 2). However, when the concentration of Artonin E was increased to 10 and 30 μM,
the effect was more pronounced, with a significant reduction (p<0.05) in the proportion of
viable cells from 92% to 76% and 54% respectively. There was also a corresponding significant
(p<0.05) increase in the proportion of cells undergoing apoptosis as the incubation time
increased from 24 to 48 hours.
Fig 2. Acridine orange and propidium iodide double staining of MDA-MB 231 breast cancer cells after
24 hour exposure. (A) Control, (B) 3 μM Artonin E. (C) 10 μM Artonin E, (D) 30 μM Artonin E and (E)
Quantification of apoptotic morphology at 24 and 48 hours. Each result is presented as mean ± SD of three
replicates. * indicates significant difference from the control of each phase (p<0.05). VC = Viable cells;
BL = Cell membrane blebbing; CC = chromatin condensation; EA = Early apoptosis; LA = late apoptosis;
MN = marginated nuclear chromatin; SN = secondary necrosis. Magnification X200.
https://doi.org/10.1371/journal.pone.0182357.g002
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Externalization of phosphatidylserine and DNA fragmentation following
Artonin E treatment
With the loss of plasma membrane integrity, the phospholipid, phosphatidyl serine (PS) trans-
locates to the outer membrane leaflet and become exposed to the extracellular environment.
This exposed phosphatidyl serine was investigated with the annexin V FITC assay, which has
high affinity for the phospholipid. From the result, after 24 hours, there was a significant
(p<0.05) increase in apoptosis in MDA-MB-231 cells when the concentration of Artonin E
was increased to 10 and 30 μM. Artonin E treatment of 3 μM did not cause any significant
increase (p>0.05) in early apoptosis when compared with the control. This apoptosis inducing
effect was enhanced as the time interval increased to 48 hours, post treatment (Fig 3).
During apoptosis, nucleases are activated to cleave internucleosomal DNA into oligomers
of 180 to 200 bp. These fragments can be visualized using agarose gel electrophoresis and veri-
fies the occurrence of apoptosis [26]-[27]. From the results, DNA fragments were visible in all
the tested concentrations of Artonin E (Fig 4) and the positive control (lanes 1±3 & 5) while
the untreated cells showed no DNA fragmentation (lane 4).
Artonin E induced G2/M breast cancer cell cycle arrest
Deregulation of the cell cycle is a notable hallmark of cancer, however, after 12 hours of incu-
bating MDA-MB 231 breast cancer cells with Artonin E, the percentage of cells in the G2/M
Fig 3. Representative histogram analysis of the annexin V-FITC in flow cytometry assay in MDA-MD-
231 cells after 24-hour and 48 hour treatment with Artonin E. Cells population in lower left quadrant are
viable, in lower right quadrant are cells at early apoptosis, in upper right quadrant at late stage of apoptosis,
and in upper left corner are cells at the necrotic stage.
https://doi.org/10.1371/journal.pone.0182357.g003
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phase increased marginally from 14.8% in the untreated control to 16.0, 18.3 and 19.05% after
treatment with 3, 10 and 30 μM Artonin E, respectively (Fig 5). There was also a significant
(p<0.05) accumulation of cells in the sub G0/G1 phase, indicating the population of cell death.
Upon increasing the time of exposure to 24 hours, the cells in the sub G0/G1 population
increased significantly with a transient accumulation at the G2/M phase at 3 and 10 μM con-
centrations of Artonin E (Fig 6).
Artonin E activates both caspases 8 and 9 and enhances the production
of total reactive oxygen species (ROS)
Caspases are major players of apoptosis. Caspases 8 and 9 are the initiators of extrinsic and
intrinsic pathway of apoptosis respectively. From the results, after 24 hours exposure of the
MDA-MB 231 cancer cells to Artonin E, there was a dose dependent increase in the activities
of both caspases 8 and 9 (Fig 7).
A consistent increase in the total ROS was observed in a concentration dependent manner
after treatment with Artonin E. The level of intracellular ROS increased significantly (p< 0.05)
from 8.3% in the untreated MDA-MB 231 cells to 19.1, 28.8 and 43.9% in cells treated with 3,
10 and 30 μM Artonin E, respectively (Fig 8).
Fig 4. DNA fragmentation of MDA-MB 231 breast cancer cells analysed in 1% agarose gel after 24
hours incubation with different concentration of Artonin E. Lanes 1–3 represents 3, 10 and 30 μM of
Artonin E, lane 4 is untreated cancer cells, lane 5 is positive control well treated with 4μg/mL camptothecin
and lane 6 is a 1kilobase DNA ladder.
https://doi.org/10.1371/journal.pone.0182357.g004
Artonin E and MDA-MB 231 triple negative breast cancer cells
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Artonin E altered the expression of apoptosis and cell cycle-related
genes in breast cancer cells
After 24 hour treatment of the MDA-MB 231 breast cancer cells with 10 μM of Artonin E,
there was a differential expression of apoptosis and cell cycle- related genes as presented in
Table 3.
Artonin E surpresses livin expression and upreguates p21 proteins dose
dependently
After treating the cancer cells with Artonin E, there was a dose dependent downregulation of
livin, a new member of the inhibitors of apoptosis, which is responsible for breast cancer pro-
gression and invasiveness. A cyclin dependent kinase inhibitor, P21 was also confirmed to be
upregulated after exposure of the triple negative breast cancer cells to Artonin E (Fig 9). Sur-
prisingly, our findings revealed the suppression of Bcl-2 in the proteome array profiling but
failed to validate it with the western blotting, which showed a rather slight induction of this
anti-apoptotic protein after several replications. This discrepancy might be owed to a possible
non-specific binding from the proteome array. The expression of p53 was rather unchanged in
Artonin E treated and untreated MDA-MB 231 cells, which harbours a mutant copy of the
protein.
Fig 5. MDA-MB 231 breast cancer cell cycle regulation after 12 hours treatment with (B) 3 μM, (C)
10 μM, and (D) 30 μM Artonin E. (A) is untreated control. (E) Analysis of cell population in the cycle phases.
Values are mean ± standard deviation of three replicates. *Means in each cell cycle phase significantly
(p<0.05) different from the control.
https://doi.org/10.1371/journal.pone.0182357.g005
Artonin E and MDA-MB 231 triple negative breast cancer cells
PLOS ONE | https://doi.org/10.1371/journal.pone.0182357 August 3, 2017 11 / 20
Discussion
Triple negative breast cancer, like other cancers, acquires certain capabilities which make it
what it is, in addition to its unique heterogeneity and invasiveness. Prominent among these
capabilities are its evasion of apoptosis and tissue invasion as well as metastasis[28]. These
attributes coupled with the low rate of survival of patients bearing triple negative breast can-
cers, fueled the search for a promising candidate that can induce apoptosis and abrogate the
intrinsic capabilities of the triple negative breast cancer. Previous literatures have reported the
isolation of Artonin E from several species of Artocarpus as well as its cytotoxic effect on the
growth of cancer cells, including the breast [29]. However, this cytotoxicity testing was only
limited to the preliminary MTT assay and to the best of our knowledge, there is no report elu-
cidating the possible molecular mechanism of action of Artonin E in MDA-MB 231 breast
cancer cells. In this study, Artonin E which we had recently reported to be drug-like [23], was
evaluated for its in vitro growth inhibition and molecular mechanism of cell death in
MDA-MB 231 triple negative breast cancer cell line. Artonin E was found to significantly
inhibit the proliferation of the breast cancer cells in a time and concentration dependent man-
ner with a half maximal inhibitory concentrations of 14.13, 13.93 and 9.77 μM at 24, 48 and 72
hours, respectively. Artonin E showed a better selectivity (about 4.5 fold) for the MDA-MB
231 cancer cells than for the normal breast epithelial cells, MCF-10A in comparison to Tamox-
ifen, a standard agent (with a selectivity of 1.08). This attribute is in contrast to abounding
Fig 6. MDA-MB 231 breast cancer cell cycle regulation after 24 hours treatment with (B) 3 μM, (C)
10 μM, and (D) 30 μM Artonin E. (A) is untreated control. (E) Analysis of cell population in the cycle phases.
Values are mean ± standard deviation of three replicate. *Means in each cell cycle phase significantly
(p<0.05) different from the control.
https://doi.org/10.1371/journal.pone.0182357.g006
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standard treatments in the market which have been reported with negligible selectivity [30].
The less toxicity towards normal breast cells offers Artonin E a better therapeutic advantage
over the standard agent, which in addition to negligible selectivity have also been reported
with uprising resistance [31].
There are different modes of cell death, including apoptosis, necrosis and autophagy. From
the results, the Artonin E-treated breast cancer cells displayed characteristic features of apo-
ptosis. This was in accordance with a report by Carou et al. (2015)[32] and Gerl and Vaux
(2005)[33], that apoptosis results in unique morphological changes like cell shrinkage, mem-
brane alteration, DNA fragmentation and nuclear condensation. In fact, compounds that
induce apoptosis are very essential in the management of cancer because evasion of apoptosis
is implicated in cancer pathogenesis [28], [34] making its induction a strategy for cancer drug
discovery[35].
The loss of membrane asymmetry during apoptosis leads to the externalization of phospha-
tidylserine. In this study, annexin V FITC and DNA binding flourochrome PI were utilized to
further strengthen the assessment of the apoptotic mode of cell death and to examine the pro-
gression of apoptotic cells [12], [36], [37]. Artonin E was seen to significantly reduce the popu-
lation of viable MDA-MB 231 breast cancer cells while increasing the population of cells
undergoing apoptosis in a concentration dependent manner. These observations implicated
apoptosis as the mode of cell death.
During apoptosis, chromosomal DNA is degraded by apoptotic endonucleases into frag-
ments [38], which becomes visible when such DNA is run in a gel electrophoresis. Here, after
treatment of the triple negative breast cancer cells, the cancer cell's DNA was seen to have
degraded as evidenced by the fragments visualized in the gel electrophoresis in comparison to
Fig 7. Detection of Caspases 8 and 9 activations in MDA-MB-231 cells treated with Artonin E after 24
hours. Values are presented as mean ± standard deviation of three replicates. *Means differ significantly
(p<0.05) from the untreated control.
https://doi.org/10.1371/journal.pone.0182357.g007
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the untreated control. This fragment induction by Artonin E, indicated an apoptotic cell death
[27], which was deduced in previous assays above. In fact, the degradation of the cancer cells
DNA discourages cell division, hence inhibiting the proliferation of the MDA-MB 231 cells.
Deregulation of cell cycle control has been evidently implicated in cancers [39±40]. This
deregulation is often mediated by alterations in the activities of cyclin-dependent kinases that
result in proliferation and chromosomal instability. Targeting the cell cycle and discovering
inhibitors of the cyclin-dependent kinases are beneficial strategies in drug discovery [41]. In
this study, the MDA-MB-231 which harbors mutant p53 was marginally arrested at the G2/M
phase after treatment with Artonin E at 12 hours with a dose dependent increase in the sub
G0/G1 phase. Artonin E-mediated G2/M phase arrest in MDA-MB 231 is suggested to be asso-
ciated with the upregulation of p21 independent of p53 as was similarly pointed out [42]. In
fact, Wafa and Pasumarthi (2015) [41], suggested that p21-mediated cell cycle inhibition can
also occur via binding and inhibition of cyclins/Cdk. This cell cycle arrest prevented the
MDA-MB-231 cells from undergoing cell division, purportedly because of the DNA fragmen-
tation induced by Artonin E. The concentration- and time-dependent accumulation of the
cancer cells at the subG0/G1 also suggested apoptosis [43]. To explore the mechanism by
which Artonin E induced apoptosis, its effect on the initiators of caspase-dependent extrinsic
and intrinsic pathways of apoptosis [44] was investigated. Caspase 8 is mostly responsible for
Fig 8. Total ROS production by MDA-MB 231 cells after treatment with Artonin E. (A) Untreated control
and (B), (C) and (D) are treatment with 3, 10 and 30 μM Artonin E, respectively. (E) is the analysis of the flow
cytometric data. Values are means ± standard deviation of three replicates. *Means differ significantly
(p<0.05) from that of untreated control. M1 = non-ROS while M2 indicate the percentage of cells with an
increase production of ROS.
https://doi.org/10.1371/journal.pone.0182357.g008
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the extrinsic pathway while caspase 9 is responsible for the intrinsic or mitochondrial pathways
[45]. From this investigation, Artonin E activated both caspases 8 and 9 significantly in a con-
centration-dependent manner. These findings suggest that in MDA-MB-231, a triple negative
breast cancer cell, the anticancer cell effect of Artonin E was via both the extrinsic and intrinsic
or mitochondrial apoptotic pathways.
The mitochondrion is one of the main sources of ROS in cells and these chemicals regulate
cell viability or mortality [12], [45±46]. Although oxygen metabolism is central to life, it has
also been implicated in the development and spread of diseases like cancer [47±48]. However,
beyond the cytotoxic concentration, ROS has been reported to trigger apoptosis [12], [49±50].
Unlike normal cells, cancer cells have restricted ability to nullify oxidative insults [51]. In this
study, ROS production in Artonin E treated MDA-MB 231 cells was enhanced. The ROS level
increased significantly from 8.3% in the untreated cells to 19.1, 28.8 and 43.9% after treatment
with 3, 10 and 30 μM of Artonin E, respectively. This upregulation of ROS indicated that one
of the mechanisms of apoptotic cell death induced by Artonin E treatment was via ROS pro-
duction, an observation similar to that of Alexandre et al. (2006)[52]. In order to gain more
insight into the molecular basis of the apoptotic signaling pathways in Artonin E-treated can-
cer cells, the gene and protein expressions were determined. From the results, the mRNA
expression of caspases 7, 8 and 9 were upregulated. These are mediators of both the extrinsic
and intrinsic pathways of apoptosis (Fig 10).
There was also an upregulation of the cyclin dependent kinase inhibitor, p21, which is sus-
pected to have contributed to the earlier observed G2/M cell cycle arrest. Artonin E was seen
Table 3. Apoptosis pathway- and cell cycle-related genes and protein expression in Artonin E treated MDA-MB 231 cells.
No. Genes/Proteins Relative expression
[%Log(fold change)]
Regulation Full name
Genes
1 Caspase 7 73.3 Up Cystein protease 7
2 Caspase 8 28.9 Up Cystein protease 8
3 Caspase 9 92.2 Up Cystein protease 9
4 Cyclin E -55.6 Down Cell cycle cyclin family member
5 P21 61.1 Up Cyclin-dependent kinase inhibitor
Proteins
1. HSP 27 11.1 Up Heat shock protein 27
2. HSP 60 -13.5 Down Heat shock protein 60
3. HSP70 -55.8 Down Heat shock protein 70
4. Livin -113.5 Down Inhibitor of apoptosis protein
5 Bcl-2 -29.1 Down B-cell lymphoma 2
6. Bcl-x -27.1 Down Bcl-2-associated X protein
7. Phospho S15 -17.6 Down Phosphorylated p53 at serine residue 15
8. Phopho S46 20.2 Up Phosphorylated p53 at serine residue 46
9. Phospho S392 26.7 Up Phosphorylated p53 at serine residue 392
10. SMAC/Diablo 23.8 Up Second mitochondria-derived activator of caspases /direct IAP
binding protein
11. TRAIL 8.5 Up TNF-related apoptosis-inducing ligand
12 HO-1/HMOX1/
HSP32
5.6 Up Heme oxygenase decyclig 1
13 cIAP-2 -18.8 Down Cellular inhibitors of apoptosis
14 Pro-caspase 3 42.7 Up Pro- Cysteine-aspartic acid protease 3
15 Cleaved caspase 3 -6.1 Down Cleaved- Cysteine-aspartic acid protease 3
https://doi.org/10.1371/journal.pone.0182357.t003
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to significantly inhibit the expression of anti-apoptotic proteins as well as inhibitors of apopto-
sis, when the human apoptosis proteome profiling was performed. From the results, Artonin E
downregulated HSP 70, Bcl-x, livin and p53 phosphorylated at position 15 (S15). These pro-
teins incidentally are overexpressed in aggressive breast cancers [52±53], indicating that the
inhibition of expression of these proteins by Artonin E in MDA-MB 231 cells had relinquish
these cancer cells of their inherent aggressiveness, enabling them to commit suicide. The
observed downregulation of cIAP2, a G2/M phase cell cycle regulator [54±55], after treatment
with Artonin E, had also been suspected as a contributing factor to the accumulation of
MDA-MB 231 breast cancer cells in the G2/M phase [56]. Other proteins, like SMAC/Diablo,
TRAIL and HO-1/HMOX1/HSP32 were upregulated in MDA-MB-231 treated with Artonin
E. These proteins are either inhibitors of the action of apoptosis inhibitors or on their own
they are inducers of apoptosis [57]. The significant upregulation of TRAIL, a tumor necrosis
factor-related apotosis inducing ligand still showed the involvement of the extrinsic pathway
in the apoptosis inducing effect of Artonin E. SMAC/DIABLO, a natural antagonist of the
inhibitors of apoptosis [58] was found to be upregulated in Artonin E-treated MDA-MB-231
cells. The upregulation of SMAC/Diablo expression can cause cell cycle arrest and increase in
caspase activities, which was part of the mechanism by which Artonin E inhibited breast can-
cer growth and induced apoptosis as observed earlier.
Fig 9. Western blot analysis of Artonin E (3, 10, and 30 μM) treated MDA-MB231 breast cancer cells
after 24 hours. (A) and the levels of protein expression quantified from the western blotting analysis of
Artonin E treated MDA-MB 231 cells using Bio-rad Image Lab software (B).
https://doi.org/10.1371/journal.pone.0182357.g009
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Western blot analysis revealed a significant (p<0.05) downregulation of livin, a novel mem-
ber of apoptosis which has been reported as a marker of breast cancer progression and invasive-
ness [58±60]. This downregulation of livin is suspected to be responsible for the antiproliferative
effect displayed by Artonin E in MDA-MB 231 cells. In an earlier experiment reported by Ou
et al. (2014) [59], a gene knockdown of livin was shown to inhibit proliferation as well as inva-
siveness of cancer cells. Artonin E inhibition of livin had played a crucial role in the inhibition
and apoptosis of the triple negative breast cancer cell line, MDA-MB 231.
Conclusions
In conclusion, we have shown for the first time that Artonin E represses livin protein, upregulates
p21 while activating caspase dependent ROS production in MDA-MB 231 triple negative breast
cancer cell line. Artonin E, in its course to circumvent the relative immortality displayed by this
cancer via apoptosis induction, affects the expression of apoptotic and cell cycle related genes
and proteins which should be individually investigated in view of ascertaining if apoptosis will be
averted in the knockdown of such genes or proteins. It is no doubt that Artonin E possesses the
potentials that can be exploited to improve the poor prognosis of triple negative breast cancers.
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